BACKGROUND: Diosgenin, a steroidal saponin from a therapeutic herb, fenugreek (Trigonellafoenum-graceum L.), has been recognized to have anticancer properties. Telomerase activity is not detected in typical healthy cells, while in cancer cell telomerase expression is reactivated, therefore providing a promising cancer therapeutic target. MATERIALS AND METHODS: We studied the inhibitory effect of diosgenin on human telomerase reverse transcriptase gene (hTERT) expression which is critical for telomerase activity. MTT- assays and qRT-PCR analysis were conducted to assess cytotoxicity and hTERT gene expression inhibition effects, respectively. RESULTS: MTT results showed that IC50 values for 24, 48 and 72h after treatment were 47, 44 and 43μM, respectively. Culturing cells with diosgenin treatment caused down-regulation of hTERT expression. DISCUSSION: These results show that diosgenin inhibits telomerase activity by down-regulation of hTERT gene expression in the A549 lung cancer cell line.
BACKGROUND:Diosgenin, a steroidal saponin from a therapeutic herb, fenugreek (Trigonellafoenum-graceum L.), has been recognized to have anticancer properties. Telomerase activity is not detected in typical healthy cells, while in cancer cell telomerase expression is reactivated, therefore providing a promising cancer therapeutic target. MATERIALS AND METHODS: We studied the inhibitory effect of diosgenin on human telomerase reverse transcriptase gene (hTERT) expression which is critical for telomerase activity. MTT- assays and qRT-PCR analysis were conducted to assess cytotoxicity and hTERT gene expression inhibition effects, respectively. RESULTS:MTT results showed that IC50 values for 24, 48 and 72h after treatment were 47, 44 and 43μM, respectively. Culturing cells with diosgenin treatment caused down-regulation of hTERT expression. DISCUSSION: These results show that diosgenin inhibits telomerase activity by down-regulation of hTERT gene expression in the A549 lung cancer cell line.
Authors: Mona S Alwhibi; Mahmoud I M Khalil; Mohamed M Ibrahim; Gehan A El-Gaaly; Ahmed S Sultan Journal: Evid Based Complement Alternat Med Date: 2017-03-22 Impact factor: 2.629